Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1960 1
1961 1
1962 1
1965 1
1967 1
1972 3
1973 1
1974 4
1975 3
1976 3
1977 2
1978 4
1979 4
1980 2
1981 2
1982 3
1983 2
1984 4
1985 2
1986 4
1987 2
1988 5
1989 8
1990 4
1991 9
1992 8
1993 3
1994 11
1995 7
1996 4
1997 9
1998 6
1999 8
2000 11
2001 5
2002 10
2003 15
2004 10
2005 16
2006 20
2007 18
2008 14
2009 10
2010 13
2011 19
2012 22
2013 27
2014 23
2015 38
2016 42
2017 39
2018 51
2019 55
2020 45
2021 54
2022 36
2023 40
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

695 results

Results by year

Filters applied: . Clear all
Page 1
Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
Locatelli F, Zugmaier G, Rizzari C, Morris JD, Gruhn B, Klingebiel T, Parasole R, Linderkamp C, Flotho C, Petit A, Micalizzi C, Mergen N, Mohammad A, Kormany WN, Eckert C, Möricke A, Sartor M, Hrusak O, Peters C, Saha V, Vinti L, von Stackelberg A. Locatelli F, et al. JAMA. 2021 Mar 2;325(9):843-854. doi: 10.1001/jama.2021.0987. JAMA. 2021. PMID: 33651091 Free PMC article. Clinical Trial.
IMPORTANCE: Blinatumomab is a CD3/CD19-directed bispecific T-cell engager molecule with efficacy in children with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). OBJECTIVE: To evaluate event-free survival in children with high-risk first-relapse …
IMPORTANCE: Blinatumomab is a CD3/CD19-directed bispecific T-cell engager molecule with efficacy in children with relapsed or refractory …
IKZF1(plus) Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia.
Stanulla M, Dagdan E, Zaliova M, Möricke A, Palmi C, Cazzaniga G, Eckert C, Te Kronnie G, Bourquin JP, Bornhauser B, Koehler R, Bartram CR, Ludwig WD, Bleckmann K, Groeneveld-Krentz S, Schewe D, Junk SV, Hinze L, Klein N, Kratz CP, Biondi A, Borkhardt A, Kulozik A, Muckenthaler MU, Basso G, Valsecchi MG, Izraeli S, Petersen BS, Franke A, Dörge P, Steinemann D, Haas OA, Panzer-Grümayer R, Cavé H, Houlston RS, Cario G, Schrappe M, Zimmermann M; TRANSCALL Consortium; International BFM Study Group. Stanulla M, et al. J Clin Oncol. 2018 Apr 20;36(12):1240-1249. doi: 10.1200/JCO.2017.74.3617. Epub 2018 Mar 2. J Clin Oncol. 2018. PMID: 29498923 Free article.
Purpose Somatic deletions that affect the lymphoid transcription factor-coding gene IKZF1 have previously been reported as independently associated with a poor prognosis in pediatric B-cell precursor (BCP) acute lymphoblastic leukemia (ALL). We have now refined the prognos …
Purpose Somatic deletions that affect the lymphoid transcription factor-coding gene IKZF1 have previously been reported as independently ass …
Peroxisome biogenesis.
Eckert JH, Erdmann R. Eckert JH, et al. Rev Physiol Biochem Pharmacol. 2003;147:75-121. doi: 10.1007/s10254-003-0007-z. Epub 2003 Mar 25. Rev Physiol Biochem Pharmacol. 2003. PMID: 12687401 Review.
Peroxisome biogenesis conceptually consists of the (a) formation of the peroxisomal membrane, (b) import of proteins into the peroxisomal matrix and (c) proliferation of the organelles. ...
Peroxisome biogenesis conceptually consists of the (a) formation of the peroxisomal membrane, (b) import of proteins into the peroxis …
Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL.
Locatelli F, Zugmaier G, Rizzari C, Morris JD, Gruhn B, Klingebiel T, Parasole R, Linderkamp C, Flotho C, Petit A, Micalizzi C, Zeng Y, Desai R, Kormany WN, Eckert C, Möricke A, Sartor M, Hrusak O, Peters C, Saha V, Vinti L, von Stackelberg A. Locatelli F, et al. Leukemia. 2023 Jan;37(1):222-225. doi: 10.1038/s41375-022-01770-3. Epub 2022 Dec 8. Leukemia. 2023. PMID: 36482128 Free PMC article. No abstract available.
The EGR3 regulome of infant KMT2A-r acute lymphoblastic leukemia identifies differential expression of B-lineage genes predictive for outcome.
Külp M, Larghero P, Alten J, Cario G, Eckert C, Caye-Eude A, Cavé H, Schmachtel T, Bardini M, Cazzaniga G, De Lorenzo P, Valsecchi MG, Bonig H, Meyer C, Rieger MA, Marschalek R. Külp M, et al. Leukemia. 2023 Jun;37(6):1216-1233. doi: 10.1038/s41375-023-01895-z. Epub 2023 Apr 26. Leukemia. 2023. PMID: 37100882 Free PMC article.
Absence of B-lineage gene expression translates to more than two-fold poorer long-term event-free survival. In conclusion, our study presents four B-lineage genes with prognostic significance, suitable for gene expression-based risk stratification of KMT2A-r iALL pa …
Absence of B-lineage gene expression translates to more than two-fold poorer long-term event-free survival. In conclusion, our study …
European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection.
Crobach MJ, Planche T, Eckert C, Barbut F, Terveer EM, Dekkers OM, Wilcox MH, Kuijper EJ. Crobach MJ, et al. Clin Microbiol Infect. 2016 Aug;22 Suppl 4:S63-81. doi: 10.1016/j.cmi.2016.03.010. Epub 2016 Jul 25. Clin Microbiol Infect. 2016. PMID: 27460910 Free article.
The commercial tests that were evaluated included enzyme immunoassays (EIAs) detecting glutamate dehydrogenase, EIAs detecting toxins A and B and nucleic acid amplification tests. Recommendations were formulated by an executive committee, and the strength of recommendation …
The commercial tests that were evaluated included enzyme immunoassays (EIAs) detecting glutamate dehydrogenase, EIAs detecting toxins A and …
Acute Lymphoblastic Leukemia in Children and Adolescents.
Peters C, Locatelli F, Bader P. Peters C, et al. In: Carreras E, Dufour C, Mohty M, Kröger N, editors. The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies [Internet]. 7th edition. Cham (CH): Springer; 2019. Chapter 72. In: Carreras E, Dufour C, Mohty M, Kröger N, editors. The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies [Internet]. 7th edition. Cham (CH): Springer; 2019. Chapter 72. PMID: 32091754 Free Books & Documents. Review.
Although the majority of children and adolescents with acute lymphoblastic leukemia (ALL) are curable with current chemotherapy regimens, poor outcome persists in some individuals (Eckert et al. 2011; von Stackelberg et al. 2011; Schrappe et al. 2012)....
Although the majority of children and adolescents with acute lymphoblastic leukemia (ALL) are curable with current chemotherapy regimens, po …
Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high-risk first relapse B-cell precursor acute lymphoblastic leukemia.
Locatelli F, Eckert C, Hrusak O, Buldini B, Sartor M, Zugmaier G, Zeng Y, Pilankar D, Morris J, von Stackelberg A. Locatelli F, et al. Pediatr Blood Cancer. 2022 Aug;69(8):e29715. doi: 10.1002/pbc.29715. Epub 2022 Apr 28. Pediatr Blood Cancer. 2022. PMID: 35482538 Clinical Trial.
BACKGROUND: Blinatumomab, a CD3/CD19 BiTE() (bispecific T cell engager) molecule, was superior to high-risk third course consolidation chemotherapy (HC3) in prolonging event-free survival (EFS) in children with high-risk first relapse B-cell precursor acute lymphoblastic l …
BACKGROUND: Blinatumomab, a CD3/CD19 BiTE() (bispecific T cell engager) molecule, was superior to high-risk third course consolidation chemo …
[Clostridioides difficile: updated recommendations].
Barbut F, Eckert C, Lalande V, Le Neindre K, Couturier J. Barbut F, et al. Rev Prat. 2022 Sep;72(7):703-709. Rev Prat. 2022. PMID: 36511953 French.
Main virulence factors of C. difficile are toxins A (TcdA) and B (TcdB). The emergence and dissemination of a new hypervirulent strain (027/NAP/BI) in 2005 has stimulated clinical and basic research on C. difficile. ...
Main virulence factors of C. difficile are toxins A (TcdA) and B (TcdB). The emergence and dissemination of a new hypervirulent strai …
695 results